Kersten Dirk 4

What Happened
Dirk Kersten, a director of Dyne Therapeutics (DYN), received a derivative award on 2026-06-05: an option covering 35,152 shares reported at $0.00. This is an equity grant (not an open‑market purchase or sale) and represents the right to acquire shares subject to vesting and other terms.

Key Details

• Transaction date: June 5, 2026; Form 4 filed June 9, 2026 (accession 0001193125-26-264021).
• Instrument: Option/derivative covering 35,152 shares; reported acquisition price $0.00.
• Vesting: The option vests in full on the earlier of (i) June 5, 2027 or (ii) the issuer’s 2027 Annual Meeting of Stockholders, subject to continued service (footnote).
• Shares owned after the transaction: not specified in the provided filing details.
• No sale or immediate exercise was reported in this filing.

Context
This is a compensation/retention award to a director rather than a purchase or sale — common practice to align directors with shareholder interests. Because it’s a time‑based option grant, it does not represent immediate buying or selling of stock; the economic impact depends on future vesting and any exercise price or sale decisions.